Cervical cytology after 2000: where to go?

C J L M Meijer, J M M Walboomers

Since the introduction of the Pap smear by George Papanicolaou, cervical cytology has become the main diagnostic tool to detect cervical cancer. Nowadays cervical cytology is not only used for the detection of overt cancer cells, but also for finding precursor lesions of cervical cancer—that is, cervical intraepithelial lesions grades I–III (CIN). The success of cervical cytology has often been demonstrated by the decrease in the prevalence of cervical cancer in countries where population based organised cervical cancer screening programmes have been introduced. However, it should be realised that the use of the Pap smear to detect cervical cancer and its precursor lesions is in fact also its tragedy, because the smears read as false negative are often precursor lesions.

Principally, cervical cytology can be used in the following ways:

- for the detection of cervical cancer and its precursor lesions, either in indicative cervical smears or in population based screening programmes;
- for the management of women with abnormal cytology; and
- to detect residual or recurrent cervical lesions after treatment.

The limited sensitivity and specificity of cervical cytology for detecting cervical cancer and its precursor lesions has been the subject of considerable debate in the last decades. To overcome these problems, several measures have already been taken to improve the end results of smear reading. These include the use of brushes instead of wooden spatulas, optimisation of staining techniques, better training of technicians, and rescreening of smears.

These measures have resulted in some improvement in the quality of reading cervical smears. However, it has now become clear that even in high quality laboratories with carefully controlled cervical smear reading, the presence of false positive and false negative smear results cannot entirely be prevented.

Given these limitations of cervical cytology, the question is whether we can improve the reading of cervical smears. The use of two new technologies may achieve such improvement:

1. The development of liquid based cytology preparations;

Liquid based cytology preparation

By sampling cervical cells in a buffer and preparing thin layers of cells by means of a special device, much better cytological preparations are obtained, lacking damaged and dead cells and showing mostly isolated cells. This leads to quicker and better smear reading (Cytec®, Autocyte®). Because not all the cells are used for the preparation of the smear, additional techniques such as HPV detection, immunohistochemical staining for cell cycle indices, tumour suppressor genes or oncogenes, and additional molecular techniques can be used, making this technique very important. As diagnostic cell groups are absent in thin layer preparations, a point of discussion is the question of how representative the smear prepared from liquid cytology is, compared with the original smear. It has been concluded that differences between a classical Pap smear and cell preparations obtained by liquid cytology are too small to influence Pap classification significantly, thus suggesting that liquid based cytology preparation is the technique to be used in the future. A disadvantage of the technique is that it is still too expensive for general use and until a significant decrease in price has been announced, the introduction of this technique into the routine setting will be considerably delayed.

Automated screening of cervical smears

Significant contributions were made by the Papnet system, whereby with the aid of neural network technology 128 areas from the most abnormal cells in a smear were digitised so that the operative can focus on these areas to obtain a rapid and reliable impression of the degree of cellular abnormality in the smear. Evaluations of the system were positive. However, that particular system will not be supported commercially in the future, and the technology has been transferred to another company, Neo-path. This company has now brought out the Autopap 300 QC system. This system, also based on neural network technology, divides the smears into five classes, varying from very suspicious of cervical cancer to normal. Depending of the sensitivity of the system and the population screened, between 25% and 40% of the smears in a population based screening programme can be passed without further screening. Neural network technology is still advancing and obviously automated cervical cytology screening based on this technology will have a place in the future.

Again, an important problem here is the price. As the costs of cervical smears are heavily controlled by health insurance companies or government institutions, the price offered at the moment is too high to implement these systems in population based screening programmes. When the costs of such systems are not adapted to the available resources, the effect will be that their implementation will result in less screening opportunities for high risk women, without a net positive effect on the
quality of cervical cancer screening. One way to overcome these problems is that screening should be performed in laboratories where at least 200 000 smears are read. For economic reasons and in order to maintain standards, it is impossible to implement these systems in smaller laboratories.

**High risk HPV testing**

Another way ahead is the use of human papillomavirus (HPV) testing. Recent investigations clearly show that persistent infection with one of the 15 high risk HPV types is necessary for the development and maintenance of CIN lesions and the subsequent progression to cervical cancer.1,5 Walboomers et al were one of the first to show that, in women with cervical cancer, high risk HPV was always present in the preceding abnormal smears and was of the same high risk HPV type as that present in the carcinoma. High risk HPV was even present in normal smears taken up to 17 years before the carcinoma. This approach overtreatment is prevented, as a substantial number of women with abnormal smears and high risk HPV negative lesions are managed using a wait-and-see policy.

Another approach that can be expected in the future is to first screen women for the presence of high risk HPV and then test only those who are high risk HPV positive for the presence of abnormal cells in the Pap smear. This approach is straightforward and leads to an enormous cost reduction.

At present, clinicians are reluctant to follow this strategy, because CIN III lesions are occasionally found to be negative for high risk HPV types and as their clinical course is unknown lawsuits are expected. However, when further evaluations of large, population based studies are published, in which the performance of high risk HPV testing and classical cytology are evaluated, this strategy will certainly be implemented. It seems logical to assume that in the future these HPV positive Pap smears will then be evaluated by automated screening systems as discussed above.13 This approach is very important for developing countries in which high quality cervical cytology laboratories are difficult to organise. Implementation of one screening round between 30 and 35 years of age in these developing countries, using liquid based high risk HPV testing followed by automated screening of thin layer preparations from women who tested high risk HPV positive, will select women for colposcopically directed biopsy and treatment. This approach could reduce the prevalence of cervical cancer in these countries by about 70%, based on the fact that high risk HPV testing can detect almost all CIN III lesions and cervical cancers. Moreover, this age (30–35 years) is more than 10 years after the peak prevalence of HPV infection in these countries, and 70% of all cervical cancers have developed by that age.

**Management of women with abnormal cytology**

A Pap smear showing mild dysplasia or atypical squamous cells of undetermined significance (ASCUS) is a problem for management as only 5–10% of women with such smear results harbour serious disease.14 High risk HPV testing helps to identify the women who have underlying CIN II or CIN III and can be referred for colposcopically directed biopsy, based on a single screening round of cytology and high risk HPV testing. An even more advanced approach was suggested by Nobbenhuis et al, who showed that in women with mild to moderate dysplasia only those who have a repeated high risk HPV positive Pap smear after six months should be referred for colposcopy, thereby preventing overtreatment of non-progressive CIN lesions. From these observations it can be concluded that the future of cervical cytology is closely linked to high risk HPV testing.

**Detection of residual or recurrent CIN lesions after treatment**

After treatment of CIN lesions by diathermic ablation or exconisation, 10–15% of the women have residual or recurrent lesions after one year.15 Moreover, by this approach overtreatment is prevented, as a sub
test used to detect such lesions at follow up. These women need colposcopically directed biopsy and treatment by therapeutic exionation of the cervix. Recent reports show that a cervical smear is not a good discriminator of the presence or absence of a CIN lesion after treatment.17

Recent studies reveal that high risk HPV is present in 96–100% of the recurrent CIN lesions.15 Preliminary studies indicate that high risk HPV testing is a much better predictor of recurrent CIN lesion than a cervical smear (Nobbenhuis MAE, et al; submitted for publication). We are presently studying, in a randomised trial, the effect of treatment of CIN lesions on the basis of either cytology or high risk HPV testing. Thus this is another area where cervical cytology meets high risk HPV testing.

Where do we go now?
The ultimate way forward will be the use of liquid based cytology preparations in combination with HPV testing and automated screening. The thin layer preparations are read by automated screening devices and high risk HPV testing can be done directly from the same liquid preparation of cervical cells. Moreover, in this approach only high risk HPV positive cytologically normal smears would be rescreened for the presence of abnormal cells, as in 5–7% of the high risk HPV positive, cytologically normal smears abnormal cells are still found.10 This will certainly reduce the number of false positive smears. Although in the next 5–10 years cervical cytology will be done in conjunction with high risk HPV testing, the results of large population based studies will finally lead to high risk HPV testing in the first place, followed by cytological screening of the HPV positive smears using automated systems. As the costs of screening for cervical cancer are tightly controlled by health insurance companies and governmental regulations, it will be difficult to implement these new technologies. At this moment the introduction of such technologies will certainly require an increase in budgets, but this will decrease after 5–10 years. It is the responsibility of the health insurance companies, government, pathologists, and gynaecologists to implement these new techniques for screening in cervical cancer at a reasonable price, because then we can go for the ultimate goal—the prevention of death from cervical cancer.

We would like to thank Drs E Risse and J Lindeman for fruitful discussion and advice. Tonia Borgmann is thanked for carefully typing the manuscript, as always.